HBV and HCV are such disparate diseases that comparing EDP-514 to any HCV drug in terms of viral-load reduction is not going to be illuminating, IMO.
In terms of curing patients with a chronic infection, HBV is a much tougher nut to crack. Paradoxically, what makes HBV so difficult to cure is what led to a relatively simple vaccine.
Market Data 
Markets 
AI
